Browse the evidence

Combination therapies improve blood sugar and lipid levels compared to GLP-1R agonists alone.

Combination therapies may be beneficial for managing blood sugar and lipid levels in patients.

Emerging gut-peptide therapies further improve metabolic health outcomes for various metabolic diseases.

Practitioners should consider gut-peptide therapies for improving metabolic health in patients with metabolic diseases.

In males with type 2 diabetes, an intensive lifestyle intervention increased testosterone levels by 14% at year 1.

Practitioners should be aware of the increase in testosterone levels in males following weight loss interventions.

Changes in waist circumference due to the intensive lifestyle intervention were a significant mediator of sex hormone changes.

Practitioners should consider waist circumference changes when evaluating hormone level changes in patients.

Tirzepatide is approved for the management of type 2 diabetes.

Healthcare providers can consider tirzepatide as a treatment option for patients with type 2 diabetes.

The treatment landscape for glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is evolving.

Practitioners should stay updated on the evolving treatments for diabetes management.

GLP-1 receptor agonists have shown early evidence of cardiovascular benefits in obese patients.

GLP-1 RAs may also be beneficial for cardiovascular health in obese patients.

Tirzepatide reduced the risk of incident major adverse cardiovascular events (MACEs) compared with liraglutide (hazard ratio, 0.58; 95% confidence interval, 0.51–0.66) and semaglutide (0.86; 0.74–0.99).

Practitioners may consider tirzepatide as a more effective option for reducing cardiovascular risks in patients with OSA and T2D.

Tirzepatide was more efficacious in younger, male patients of White ethnicity.

Treatment strategies may need to be tailored based on demographic factors for optimal outcomes.

Tirzepatide reduced incident obstructive sleep apnea (OSA) compared with liraglutide (0.89; 0.82–0.97) but not semaglutide (0.94; 0.86–1.02).

Tirzepatide may be beneficial in managing both diabetes and associated sleep apnea in patients.

GLP-1 agonists had a good safety profile with most adverse effects being mild.

GLP-1 agonists can be considered a safe option for weight management in obese IBD patients.

Incretin-based therapies were associated with a mean reduction in the apnea-hypopnea index (AHI) of -14.45 events/h.

Incretin-based therapies may effectively reduce AHI in OSA patients, improving sleep quality.

Incretin-based therapies showed a greater effect on AHI compared to usual care, with a mean difference of -11.61 events/h.

Incretin-based therapies may be more effective than usual care for improving AHI in OSA patients.

Tirzepatide, a GLP-1/GIP receptor co-agonist, is approved for type 2 diabetes and shows significant reductions in glycemia and body weight compared to GLP-1R mono-agonism with semaglutide.

Tirzepatide may be a more effective treatment option for managing blood sugar and weight in patients with type 2 diabetes.

All 3 eligible maintenance doses of tirzepatide (5, 10, and 15 mg once a week) were effective in increasing total cholesterol (TC), HDL-C, VLDL-C, triglyceride (TG), and waist circumference (WC) changes from baseline compared with control agents.

Tirzepatide may be considered as an effective treatment option for improving lipid profiles and waist circumference in patients with type 2 diabetes.

Only 5 mg once-weekly tirzepatide could induce significant alteration in LDL-C before sensitivity analysis.

Clinicians should note that the 5 mg dose of tirzepatide may be more effective for lowering LDL-C compared to higher doses.

Tirzepatide had superiority over placebo or other antidiabetic agents in controlling lipid and waist circumference levels.

Tirzepatide may be a preferred treatment option for improving lipid profiles and waist circumference in patients with type 2 diabetes.

GLP-1RA use in MUHO is associated with a lower risk of ischemic stroke (HR 0.921) compared to non-use.

GLP-1RAs may be beneficial for reducing ischemic stroke risk in MUHO patients.

Patients with metabolically healthy obesity (MHO) have a markedly lower risk of clinical events compared to those with metabolically unhealthy obesity (MUHO).

Understanding the risk differences can guide treatment decisions for obesity management.

Testosterone replacement therapy significantly decreased waist circumference from 88.6 ± 13.1 cm to 83.9 ± 12.9 cm (P < 0.01).

Practitioners can consider testosterone replacement therapy for reducing waist circumference in hypogonadal patients.

Testosterone replacement therapy resulted in a significant increase in lean body mass from 46,906 ± 8,876 gm to 50,083 ± 7,590 gm (P < 0.001).

Practitioners may use testosterone replacement therapy to enhance lean body mass in hypogonadal patients.

Semaglutide has a favorable safety profile across diverse patient populations and treatment durations.

Clinicians can consider semaglutide as a safe option for managing type 2 diabetes and obesity.

Remission rates for diabetes after bariatric surgery range between 40 and 80%.

Practitioners can expect a significant proportion of patients to achieve diabetes remission post-surgery.

Females tended to lose more weight (Mean = 9.75) than males (Mean = 8.41).

Practitioners may consider gender differences when designing weight-loss interventions.